EGFR-IN-7 是一种有效的选择性EGFR激酶抑制剂,具有口服活性。EGFR-IN-7 对 EGFR (WT) 和 EGFR (突变体 C797S/T790M/L858R) 具有抑制作用,IC50值分别为 7.92 nM 和 0.218 nM。EGFR-IN-7 可用于各种癌症的研究。
生物活性 | EGFR-IN-7 is a potent, selective and orally activeEGFRkinaseinhibitor. EGFR-IN-7 has inhibitory effect for forEGFR(WT) andEGFR(mutant C797S/T790M/L858R) withIC50values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 can be used for the research of various cancers[1]. |
IC50& Target[1] | EGFR (WT) 7.92 nM (IC50) | EGFR (C797S/T790M/L858R) 0.218 nM (IC50) |
|
体外研究 (In Vitro) | EGFR-IN-7 (compound 34) (10 mM) has a strong inhibitory effect on the enzymatic activity of EGFR (WT), EGFR (Δ19del/T790M/C797S) and EGFR (C797S/T790M/L858R) with IC50values of 7.92 nM, 0.218 nM and 0.16 nM, respectively[1]. EGFR-IN-7 (1 mM) has excellent selectivity for EGFR (WT) in A431 cells with an IC50value of 154 nM[1]. EGFR-IN-7 (10 μM-0.508 nM) has a good inhibitory effect on cells of the Ba/F 3 (EGFRΔ19del/T790M/C797S) triple mutant with an IC50value of 22 nM[1]. EGFR-IN-7 (10 μM or 100 μM) has inhibition of phosphorylation activity of pEGFR Ba/F 3 (EGFRΔ19del/T790M/C797S) cells with an IC50value of 19 nM[1].
Cell Proliferation Assay[1] Cell Line: | A431 cells; Ba/F 3 (EGFRΔ19del/T790M/C797S) suspension cells | Concentration: | 1 mM; 10 μM-0.508 nM | Incubation Time: | 3 days | Result: | Inhibited proliferation in cells. |
|
体内研究 (In Vivo) | EGFR-IN-7 (compound 34; 5-45 mg/kg; p.o.; daily; for 13 days) shows potent anti-tumor activity in a subcutaneously implanted Ba/F 3 (Δ19del/T790M/C797S)-derived xenograft (CDX) BALB/c nude mouse resistance model[1]. EGFR-IN-7 (25 and 50 mg/kg; p.o.; daily, for 3 weeks) has a significant inhibitory effect on tumor growth in the mouse subcutaneous xenograft PC-9 (Δ19del) model[1].
Animal Model: | Ba/F 3 (Δ19del/T790M/C797S)-derived xenograft (CDX) BALB/c nude mice (female, 6-8 weeks, 18-22 g)[1] | Dosage: | 5, 15, 45 mg/kg | Administration: | Oral administration, daily, for 13 days | Result: | Significantly increased the half-life, the amount of exposure in plasma and tissues, had good pharmacokinetic effects in mice. |
Animal Model: | Subcutaneous xenograft PC-9 (Δ19del) model[1] | Dosage: | 0-9 days: 50 mg/kg, 10-21 days: 25 mg/kg | Administration: | Oral administration, once a day, 3 weeks | Result: | Had a significant inhibitory effect on tumor growth, had a tumor-reducing effect and showed good antitumor efficacy. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 5 mg/mL(7.20 mM;ultrasonic and warming and adjust pH to 5 with 0.1 M HCL and heat to 60℃) 配制储备液 1 mM | 1.4397 mL | 7.1984 mL | 14.3968 mL | 5 mM | 0.2879 mL | 1.4397 mL | 2.8794 mL | 10 mM | --- | --- | --- |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 1.25 mg/mL (1.80 mM); Clear solution
此方案可获得 ≥ 1.25 mg/mL (1.80 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 1.25 mg/mL (1.80 mM); Clear solution
此方案可获得 ≥ 1.25 mg/mL (1.80 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 1.25 mg/mL (1.80 mM); Clear solution
此方案可获得 ≥ 1.25 mg/mL (1.80 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|